STOCK TITAN

Regeneron Pharmaceuticals Inc - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.

The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.

Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.

Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.

For more information, visit Regeneron Pharmaceuticals.

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) has secured a new agreement to supply an additional 1.4 million doses of its COVID-19 treatment REGEN-COV to the U.S. government. This brings the total purchased doses to nearly 3 million. Authorized for use in high-risk patients, REGEN-COV has shown to reduce hospitalization or death risk by 70% when administered early. The current agreement, priced at $2,100 per dose, will see deliveries start in September 2021, primarily in Q4 2021. Regeneron will record all net sales associated with this agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced positive Phase 2 trial results for high-dose aflibercept in treating wet age-related macular degeneration (AMD). The trial met its primary safety endpoint, showing no new safety signals. In a cohort of 106 patients, 43.4% in the aflibercept 8 mg group exhibited no retinal fluid compared to 26.4% in the 2 mg EYLEA group. Phase 3 trials for wet AMD and diabetic macular edema are fully recruited, with results anticipated in late 2022, assessing safety and efficacy for up to two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
Rhea-AI Summary

Regeneron Pharmaceuticals has received Conditional Marketing Authorization from the UK MHRA for its antibody cocktail, REGEN-COV™, to prevent and treat acute COVID-19 infection. This approval enables distribution across the UK, including Northern Ireland, targeting high-risk patients, particularly those unsuitable for vaccines. Over the past week, Regeneron distributed over 130,000 doses in the U.S. The company submitted the first Biologics License Application to the FDA for REGEN-COV, with the second submission focusing on hospitalized patients expected later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
covid-19
-
Rhea-AI Summary

Regeneron Pharmaceuticals reported a remarkable 163% increase in total revenues, reaching $5.14 billion in Q2 2021. This surge includes $2.76 billion from REGEN-COV. Excluding REGEN-COV, revenues grew 22%. Notable product performances include EYLEA, with a 28% increase to $1.42 billion, and Dupixent, which rose 59% to $1.50 billion. GAAP diluted EPS also soared to $27.97. The FDA updated the Emergency Use Authorization for REGEN-COV, and Libtayo's Phase 3 trial in lung cancer showed significant survival benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
Rhea-AI Summary

On August 5, 2021, Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi announced the early termination of a Phase 3 trial for Libtayo, a PD-1 inhibitor, after it achieved its primary endpoint of improved overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients. The combination of Libtayo and chemotherapy increased median OS from 13 to 22 months, representing a 29% reduction in the risk of death. Data from the trial will support regulatory submissions in the U.S. and EU. The trial involved 466 patients with various PD-L1 expression levels, demonstrating substantial efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
Rhea-AI Summary

Regeneron Pharmaceuticals announced positive results from a Phase 3 trial for REGEN-COV (casirivimab and imdevimab) published in the New England Journal of Medicine. The trial demonstrated an 81% reduction in symptomatic COVID-19 infections among household contacts of infected individuals (p<0.001), with a 93% reduction observed after the first week. The study's results affirm the treatment's effectiveness against prevalent variants, addressing the unmet needs of immunocompromised patients. REGEN-COV's usage has surged, surpassing 50,000 weekly doses in the U.S., as the company continues collaborations to enhance global supply.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced the winners of the 2021 Regeneron Prize for Creative Innovation, recognizing postdoctoral fellows and graduate students in biomedical research. Sergey D. Stavisky from Stanford University and Nitsan Goldstein from the University of Pennsylvania won in their respective categories, each receiving $50,000, with a $5,000 donation to their institutions. This initiative aims to foster creativity in scientific research, particularly in areas like neurology, which have gained importance during the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals announced that the FDA expanded the Emergency Use Authorization (EUA) for REGEN-COV (casirivimab and imdevimab), allowing it for post-exposure prophylaxis in high-risk individuals exposed to COVID-19. Phase 3 data showed an 81% reduction in symptomatic infections among close contacts. REGEN-COV is the only authorized COVID-19 antibody therapy for both treatment and prevention, retaining efficacy against key variants. The use of REGEN-COV is growing rapidly in the U.S. to combat ongoing outbreaks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi have announced that Dupixent (dupilumab) has met primary and key secondary endpoints in a pivotal Phase 3 trial for chronic spontaneous urticaria (CSU). The study demonstrated a nearly twofold reduction in itch and urticaria activity at 24 weeks for patients receiving Dupixent alongside antihistamines. Approximately 300,000 people in the U.S. suffer from moderate-to-severe CSU. The trial showcased Dupixent’s well-established safety profile, with similar adverse events reported between Dupixent and placebo groups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $715.13 as of December 23, 2024.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 78.3B.

What types of diseases does Regeneron Pharmaceuticals focus on?

Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

What are some of Regeneron's key products?

Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.

Who are some of Regeneron's notable collaborators?

Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.

What recent financial steps has Regeneron taken?

Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.

How does Regeneron leverage genetic medicine?

Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.

What is the significance of Eylea in Regeneron's product portfolio?

Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.

What advancements has Regeneron made in gene therapy?

Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.

What is Dupixent used for?

Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.

What technologies does Regeneron use for drug development?

Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.

How does Regeneron contribute to scientific discovery?

Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.

Regeneron Pharmaceuticals Inc

Nasdaq:REGN

REGN Rankings

REGN Stock Data

78.31B
106.22M
1.56%
90.64%
1.63%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TARRYTOWN